MedTrace Logo

Impact of Airways Function After HFNC Evaluated by IOS

NCT05130112 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2021-11-22

No results posted yet for this study

Summary

In addition to pharmacological treatment, nonpharmacological treatment with high-flow nasal cannula (HFNC) may play a vital role in the treatment of patients with chronic obstructive pulmonary disease (COPD). The impulse oscillation system (IOS) is new noninvasive technique to measure the impedance of different portions of the airway with higher sensitivity than that of the conventional pulmonary function test (PFT). However, whether IOS is an appropriate technique to evaluate the efficacy of HFNC in improving the impedance of peripheral small airways in patients with COPD is unclear.

Conditions

  • Small Airway Disorders
  • COPD

Interventions

DEVICE

high flow nasal cannula and nasal cannula

HFNC was administered using the MyAIRVO 2 device (Fisher \& Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher \& Paykel Healthcare, Auckland, New Zealand) is administered for 10 min.. NC is administered for 10 min.

Sponsors & Collaborators

  • Fu Jen Catholic University Hospital

    lead OTHER

Principal Investigators

  • Yen-Liang Kuo, MD · Fu Jen Catholic University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-13
Primary Completion
2020-03-31
Completion
2020-09-09
FDA Device
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05130112 on ClinicalTrials.gov